WOCKHARDT LTD (WOCKPHARMA): Financials & Fundamentals History

Share price

Closing priceAdjusted for splits and bonus issues.

3M1Y3YAll

₹2,031.5 latest close · +4.8% over the last 90 sessions

₹2,031.5 month-end · +64.5% over 12 months

₹2,031.5 month-end · +488.3% over 3 years

₹2,031.5 month-end · +399.2% since Jan '19

52-week range ₹1086.70 to ₹2422.30 · 1-year volatility 47.8%

Was the rally earned?

+406%share price, 5 yearsMultiple-driven

Partly.

Most of the rise came from investors paying a higher multiple (P/E 8.4x to 80.7x); per-share earnings took off 160 points.
The share count rose 13%.

Net profit growth-130 ptsNet profit fell about 41%, which lowers the price.

P/E change+566 ptsThe P/E rose from 8.4x to 80.7x, which lifts the price.

Share count change-30 ptsShare count rose 13%, which lowers the price.

What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Not shown for 1 year and 3 years: earnings were negative at one end, or there is not enough history.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with SUN PHARMACEUTICAL INDUSTRIES

How rough has the ride been?

Maximum drawdown-79.4%recovered 2024-07

1-year volatility47.8%annualised

Beta vs sector index1.493-year daily, correlation 0.40

Volume spikes3last 90 sessions, 5x the 50-day median

Drawdown from peak

Largest drawdowns

-79.4% (2021-05 peak to 2023-03 low, recovered 2024-07)

-70.5% (2019-01 peak to 2020-03 low, recovered 2020-12)

-39.9% (2025-06 peak to 2026-03 low, recovered 2026-05)

Most recent volume spikes

2026-09-23: 5.8x the 50-day median, price +6.6% that day

2026-09-07: 7x the 50-day median, price +5.7% that day

2026-09-04: 5.7x the 50-day median, price +7.1% that day

Beta is the slope of daily returns against a market-cap-weighted index of the sector's other listed companies, built from today's constituents (so it excludes companies no longer listed).

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

ROCE29th▲ 16 pts vs a year ago
Op. margin63rd▲ 34 pts vs a year ago
Revenue growth69th▲ 36 pts vs a year ago
EPS growth4th
Debt/equity ↓28thflat vs a year ago
Cash cycle ↓45th▼ 14 pts vs a year ago
P/E ↓16th
12M momentum85th▲ 29 pts vs a year ago

Rank history

ROCE

Op. margin

Revenue growth

EPS growth

Debt/equity ↓

Cash cycle ↓

P/E ↓

12M momentum

Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26

Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

What is the price implying?

~33%annual earnings growth implied by the price

At a P/E of 80.7x, the price would imply about 32.5%/yr earnings growth for 10 years under the same assumptions, but it is not ranked.

Fewer than six years of annual earnings are available, which is too little to measure delivered growth.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect.

What prices imply across Health Technology The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov: ₹2031.50
P/E: 80.7x
ROCE: 8.0%
Market Cap: ₹33016 cr
Revenue (TTM): ₹3564 cr
P/S: 9.3x
P/B: 6.7x
ROE: 8.3%
Operating Margin: 21.0%
Debt / Equity: 0.5x
Promoter Holding: 49.1%
12M Momentum: 64.5%

52-week range

₹1086.70₹2422.30

71% of the way from its 52-week low to its high

Price risk

1Y volatility

47.8%

Beta vs sector

1-year daily

1.14

Balance sheet & cash

Interest cover

operating profit ÷ interest

3.1x

Cash from profit, 3Y

operating cash flow ÷ net profit

2.12x

Share count, 1Y

unchanged

Are profits backed by cash?

3 of 6checks within range1 beyond a threshold

Other income reliance29%Near threshold

Other income as a share of pre-tax profit (trailing twelve months): 28.9%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate10%Near threshold

Median quarterly effective tax rate over about 2.5 years: 9.5%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.

Cash conversion—Not enough data

Not enough reported data to compute this.

Free cash flow4 of 5 yrsWithin range

Fiscal years with positive free cash flow in the last 5: 4. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history-17 daysWithin range

Debtor days are below the median of the previous three fiscal years by 17 days (64 vs 81). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress85% of fixed assetsBeyond threshold

Capital work-in-progress is 85% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days-58 days / 2 yrsWithin range

Days payable changed by -58 over two years. Bands: rise of up to 30 days; more than 30 days.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

Over 3 years, DIIs added 9.0 pts; promoters trimmed 6.0 pts; FIIs added 4.2 pts.

Holdings, Jun '26

How each group changed

GroupSep '23Jun '26Change

Promoters55.1%49.1%-6.0 pts

FIIs3.0%7.2%+4.2 pts

DIIs0.2%9.2%+9.0 pts

Public and others41.6%34.4%-7.2 pts

Number of shareholders

1.7 lakhshareholders-4% since Sep '23

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What happened next to similar setups

−2.1%typical 12-month return vs the marketNot meaningfully different from the base rate

We found 50 past situations where a non-financial company looked like WOCKHARDT LTD today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
Over the following 12 months the middle half of them returned −18% to +36% vs the market, against −5% for all non-financial companies in the same months.
The gap against the base rate (+2.8%, 80% range −9.1% to +14.7%) is within what chance and overlapping periods produce.

Where the 50 outcomes landed

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 3 beyond the range shown, drawn at the edge

Similar setups' median

−2.1%

All companies' median

−4.9%

Beat the market

48% vs 44%

50 past situations · 50 companies · 28 months · 2020–2025

The closest matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
SHILPAMED Health Technology	Jun 2025	111x	8%	+56%	−10%	+34%
LAURUSLABS Health Technology	Sep 2025	89x	9%	+82%	−10%	+134%
ORCHPHARMA Health Technology	Feb 2024	104x	5%	+204%	−4%	−15%
TRIDENT Process Industries	Jan 2022	99x	10%	+320%	−10%	−43%
TARIL Producer Manufacturing	Apr 2025	92x	15%	+58%	−20%	−37%

Show the other 3 matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
DLF Finance	Feb 2020	34x	5%	+23%	−23%	+10%
ITI Electronic Technology	May 2020	80x	7%	−13%	−21%	−14%
ANURAS Health Technology	May 2023	77x	11%	+70%	−4%	−54%

How reliable is this?

Matched on P/E, P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: drawdown from 12-month high, P/E and debt/equity. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to WOCKHARDT LTD. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

Feature	Weight	Non-financial	Financial
P/E	1	yes	yes
P/S	1	yes	—
P/B	1	—	yes
ROCE	1	yes	—
operating margin	1	yes	—
ROE	1	—	yes
debt/equity	0.75	yes	—
interest cover	0.5	yes	—
revenue growth	0.75	yes	yes
12-month momentum	1	yes	yes
drawdown from 12-month high	0.75	yes	yes
size	0.75	yes	yes
volatility	0.5	yes	yes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What else looks like this?

Companies with the most similar financial profile today, regardless of industry.

HFCLHFCL

Electronic Technology

70%similar

market capoperating margin

RAMKRISHNA FORGINGSRKFORGE

Producer Manufacturing

64%similar

revenue growthrevenue

PCBL CHEMICALPCBL

Process Industries

59%similar

ROCEvolatility

DYNAMATIC TECHNOLOGIESDYNAMATECH

Producer Manufacturing

58%similar

volatilityrevenue growth

SANSERA ENGINEERINGSANSERA

Producer Manufacturing

56%similar

revenueP/E

SHILPA MEDICARESHILPAMED

Health Technology

62%similar

P/Emarket cap

AARTI PHARMALABSAARTIPHARM

Health Technology

56%similar

volatilitydebt/equity

ONESOURCE SPECIALTY PHARMAONESOURCE

Health Technology

47%similar

market capvolatility

Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.

What changed?

30 events since Jul '23

2026
SepPriceVolume reached 7.0x its 50-day median on 2026-09-07; price +5.7% that day.
JunPeer rankMoved into the 3rd quartile of Health Technology on ROCE (from the bottom quartile).
MayPriceRegained the 2025-06 peak, 2 months after the low.
MayPriceVolume reached 47.4x its 50-day median on 2026-05-06; price +11.7% that day.
MarResultsEPS (TTM) turned positive.
MarPriceFell 40% from the Jun 2025 peak to the Mar 2026 low.
MarPriceVolume reached 6.0x its 50-day median on 2026-03-25; price +5.1% that day.
2025
DecPeer rankMoved into the 2nd quartile of Health Technology on operating margin (from the 3rd quartile).

Show 22 earlier events

2025
DecPriceVolume reached 53.0x its 50-day median on 2025-12-02; price +1.5% that day.
SepPeer rankMoved into the 3rd quartile of Health Technology on operating margin (from the bottom quartile).
SepPriceVolume reached 35.9x its 50-day median on 2025-09-29; price +17.1% that day.
JulSharesShare count is up 5.2% over 12 months.
JunPriceRegained the 2025-02 peak, 4 months after the low.
JunPeer rankSlipped to the bottom quartile of Health Technology on operating margin (from the 2nd quartile).
JunPriceVolume reached 21.7x its 50-day median on 2025-06-11; price +18.4% that day.
MarPromoterPromoter holding fell 2.9 pts to 49.1% (largest drop since 2024-06).
MarInstitutionsFII + DII holding rose 6.0 pts over 2 quarters to 16.4%.
MarPeer rankMoved into the 2nd quartile of Health Technology on operating margin (from the 3rd quartile).
FebPriceFell 30% from the Feb 2025 peak to the Feb 2025 low.
2024
OctPriceVolume reached 8.8x its 50-day median on 2024-10-15; price +3.3% that day.
SepPeer rankMoved into the 3rd quartile of Health Technology on operating margin (from the bottom quartile).
JulPriceRegained the 2021-05 peak, 16 months after the low.
JulPriceVolume reached 19.5x its 50-day median on 2024-07-01; price +20.0% that day.
JunPromoterPromoter holding fell 3.3 pts to 51.6%.
JunInstitutionsFII + DII holding rose 7.1 pts over 2 quarters to 10.3%.
JunSharesShare count is up 6.9% over 12 months.
JunPriceVolume reached 7.1x its 50-day median on 2024-06-27; price +0.4% that day.
FebPriceVolume reached 7.1x its 50-day median on 2024-02-19; price +13.2% that day.
2023
NovPriceVolume reached 39.1x its 50-day median on 2023-11-16; price +14.2% that day.
JulPriceVolume reached 7.8x its 50-day median on 2023-07-04; price +1.6% that day.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history95 months · 2019-01 to 2026-11

Month	P/E	Revenue (TTM)	ROE	ROCE	Debt / Equity
2026-11	80.7x	₹3564 cr	8.3%	8.0%	0.5x
2026-10	75.5x	₹3564 cr	8.4%	8.0%	0.5x
2026-09	84.1x	₹3564 cr	8.4%	8.0%	0.5x
2026-08	143.7x	₹3373 cr	4.0%	8.0%	0.5x
2026-07	149.5x	₹3373 cr	4.0%	8.0%	0.5x
2026-06	148.1x	₹3373 cr	4.0%	8.0%	0.5x
2026-05	1504.7x	₹3151 cr	0.5%	4.0%	0.5x
2026-04	1033.8x	₹3151 cr	0.5%	4.0%	0.5x
2026-03	870.9x	₹3151 cr	0.5%	4.0%	0.5x
2026-02	—	₹2984 cr	-1.2%	4.0%	0.5x
2026-01	—	₹2984 cr	-1.2%	4.0%	0.5x
2025-12	—	₹2984 cr	-1.2%	4.0%	0.5x
2025-11	—	₹3011 cr	-3.4%	4.0%	0.5x
2025-10	—	₹3011 cr	-3.4%	4.0%	0.5x
2025-09	—	₹3011 cr	-3.4%	4.0%	0.5x
2025-08	—	₹3012 cr	-1.3%	4.0%	0.5x
2025-07	—	₹3012 cr	-1.3%	4.0%	0.5x
2025-06	—	₹3012 cr	-1.3%	4.0%	0.5x
2025-05	—	₹2969 cr	-5.6%	-1.0%	0.7x
2025-04	—	₹2969 cr	-5.6%	-1.0%	0.7x
2025-03	—	₹2969 cr	-5.6%	-1.0%	0.7x
2025-02	—	₹2949 cr	-8.8%	-1.0%	0.7x
2025-01	—	₹2949 cr	-8.8%	-1.0%	0.7x
2024-12	—	₹2949 cr	-8.8%	-1.0%	0.7x
2024-11	—	₹2893 cr	-10.5%	-1.0%	0.7x
2024-10	—	₹2893 cr	-10.5%	-1.0%	0.7x
2024-09	—	₹2893 cr	-10.5%	-1.0%	0.7x
2024-08	—	₹2798 cr	-14.1%	-1.0%	0.7x
2024-07	—	₹2798 cr	-14.1%	-1.0%	0.7x
2024-06	—	₹2798 cr	-14.1%	-1.0%	0.7x
2024-05	—	₹2651 cr	-18.5%	0.0%	0.7x
2024-04	—	₹2651 cr	-18.5%	0.0%	0.7x
2024-03	—	₹2651 cr	-18.5%	0.0%	0.7x
2024-02	—	₹2651 cr	-18.5%	0.0%	0.7x
2024-01	—	₹2651 cr	-18.5%	0.0%	0.7x
2023-12	—	₹2651 cr	-18.5%	0.0%	0.7x
2023-11	—	₹2651 cr	-18.5%	0.0%	0.7x
2023-10	—	₹2651 cr	-18.5%	0.0%	0.7x
2023-09	—	₹2651 cr	-18.5%	0.0%	0.7x
2023-08	—	₹2651 cr	-18.5%	0.0%	0.7x
2023-07	—	₹2651 cr	-18.5%	0.0%	0.7x
2023-06	—	₹2651 cr	-18.5%	0.0%	0.7x
2023-05	—	₹3230 cr	-7.2%	1.0%	0.6x
2023-04	—	₹3230 cr	-7.2%	1.0%	0.6x
2023-03	—	₹3230 cr	-7.2%	1.0%	0.6x
2023-02	—	₹3230 cr	-7.2%	1.0%	0.6x
2023-01	—	₹3230 cr	-7.2%	1.0%	0.6x
2022-12	—	₹3230 cr	-7.2%	1.0%	0.6x
2022-11	—	₹3230 cr	-7.2%	1.0%	0.6x
2022-10	—	₹3230 cr	-7.2%	1.0%	0.6x
2022-09	—	₹3230 cr	-7.2%	1.0%	0.6x
2022-08	—	₹3230 cr	-7.2%	1.0%	0.6x
2022-07	—	₹3230 cr	-7.2%	1.0%	0.6x
2022-06	—	₹3230 cr	-7.2%	1.0%	0.6x
2022-05	5.4x	₹2708 cr	20.4%	-3.0%	0.8x
2022-04	5.8x	₹2708 cr	20.4%	-3.0%	0.8x
2022-03	5.5x	₹2708 cr	20.4%	-3.0%	0.8x
2022-02	6.6x	₹2708 cr	20.4%	-3.0%	0.8x
2022-01	7.6x	₹2708 cr	20.4%	-3.0%	0.8x
2021-12	8.0x	₹2708 cr	20.4%	-3.0%	0.8x
2021-11	8.4x	₹2708 cr	20.4%	-3.0%	0.8x
2021-10	8.3x	₹2708 cr	20.4%	-3.0%	0.8x
2021-09	8.8x	₹2708 cr	20.4%	-3.0%	0.8x
2021-08	7.8x	₹2708 cr	20.4%	-3.0%	0.8x
2021-07	10.2x	₹2708 cr	20.4%	-3.0%	0.8x
2021-06	10.0x	₹2708 cr	20.4%	-3.0%	0.8x
2021-05	—	₹2844 cr	-1.6%	-1.0%	1.3x
2021-04	—	₹2844 cr	-1.6%	-1.0%	1.3x
2021-03	—	₹2844 cr	-1.6%	-1.0%	1.3x
2021-02	—	₹2844 cr	-1.6%	-1.0%	1.3x
2021-01	—	₹2844 cr	-1.6%	-1.0%	1.3x
2020-12	—	₹2844 cr	-1.6%	-1.0%	1.3x
2020-11	—	₹2844 cr	-1.6%	-1.0%	1.3x
2020-10	—	₹2844 cr	-1.6%	-1.0%	1.3x
2020-09	—	₹2844 cr	-1.6%	-1.0%	1.3x
2020-08	—	₹2844 cr	-1.6%	-1.0%	1.3x
2020-07	—	₹2844 cr	-1.6%	-1.0%	1.3x
2020-06	—	₹2844 cr	-1.6%	-1.0%	1.3x
2020-05	—	₹3566 cr	-8.1%	-1.0%	1.3x
2020-04	—	₹3566 cr	-8.1%	-1.0%	1.3x
2020-03	—	₹3566 cr	-8.1%	-1.0%	1.3x
2020-02	—	₹3566 cr	-8.1%	-1.0%	1.3x
2020-01	—	₹3566 cr	-8.1%	-1.0%	1.3x
2019-12	—	₹3566 cr	-8.1%	-1.0%	1.3x
2019-11	—	₹3566 cr	-8.1%	-1.0%	1.3x
2019-10	—	₹3566 cr	-8.1%	-1.0%	1.3x
2019-09	—	₹3566 cr	-8.1%	-1.0%	1.3x
2019-08	—	₹3566 cr	-8.1%	-1.0%	1.3x
2019-07	—	₹3566 cr	-8.1%	-1.0%	1.3x
2019-06	—	₹3566 cr	-8.1%	-1.0%	1.3x
2019-05	—	₹3937 cr	-23.4%	-1.0%	1.3x
2019-04	—	₹3937 cr	-23.4%	-1.0%	1.3x
2019-03	—	₹3937 cr	-23.4%	-1.0%	1.3x
2019-02	—	₹3937 cr	-23.4%	-1.0%	1.3x
2019-01	—	₹3937 cr	-23.4%	-1.0%	1.3x

Methodology and data notes